Report Highlights

Calciphylaxis in the United States: Market Overview

The U.S. calciphylaxis market is a specialist niche within nephrology, valued at USD 186 million in 2024 across sodium thiosulfate, calcimimetics, phosphate binders and wound care. Calciphylaxis, or calcific uremic arteriolopathy, affects an estimated 1 to 4 percent of dialysis patients, and the at-risk pool is the more than 800,000 Americans with end-stage kidney disease tracked by the United States Renal Data System. Pricing is shaped less by open competition than by Medicare rules administered by the Centers for Medicare and Medicaid Services.

Government has been the dominant force in the market's current form. Medicare's ESRD Prospective Payment System, created by the Medicare Improvements for Patients and Providers Act of 2008, folds most dialysis drugs into a fixed monthly bundle, pushing providers toward cheaper oral agents. Private companies have led product development: Amgen's Parsabiv (approved 2017) and Ardelyx's Xphozah (approved 2023) were funded by sponsors, not public grants. Sodium thiosulfate remains largely off-label, so outsourcing facilities supply much of the calciphylaxis-specific volume.

Policy-Driven Growth in Calciphylaxis Care in the United States

The most powerful demand lever is the ESRD Prospective Payment System, authorised under the Medicare Improvements for Patients and Providers Act of 2008 and implemented from 2011. Under its monthly bundle, providers absorb drug costs, so phosphate and calcium control becomes a financial priority to avoid the hospitalisations that calciphylaxis triggers. CMS's CY2025 ESRD PPS final rule incorporated oral-only drugs, including calcimimetics and phosphate binders, into the bundle from January 1, 2025, extending that incentive to prescribing decisions that previously sat under Medicare Part D.

A second mechanism is the Drug Quality and Security Act of 2013, which created FDA-registered 503B outsourcing facilities able to produce sterile sodium thiosulfate in bulk for hospitals and clinics. Compounded supply removes the bottleneck of patient-specific preparation, letting providers treat calciphylaxis lesions at scale. Third, Part D under the Medicare Modernization Act of 2003 (Pub. L. 108-173) has covered cinacalcet since 2006, and generic entry from 2018 reduced prices enough to make long-term calcimimetic therapy affordable for prevention.

Regulatory Barriers and Compliance Costs in Calciphylaxis Care

Compounded sodium thiosulfate faces the heaviest compliance burden. The Food and Drug Administration regulates it under Section 503A of the Federal Food, Drug, and Cosmetic Act for patient-specific prescriptions and under Section 503B for outsourcing facilities, while state boards of pharmacy license dispensing pharmacies. Sterile compounding must meet USP General Chapter <797> standards, which adds facility, environmental-monitoring and staffing costs that limit entry for smaller pharmacies.

Coverage adds a second barrier. Medicare Administrative Contractors apply local coverage determinations to wound therapies, and hyperbaric oxygen therapy is assessed against National Coverage Determination 20.29 criteria, which do not list calciphylaxis as a standard indication. Part D plans must issue standard coverage determinations within 72 hours and expedited determinations within 24 hours, so prior authorisation delays infusions. Dialysis facilities must also meet the 42 CFR Part 494 Conditions for Coverage, documenting every mineral-bone treatment plan.

Policy-Created Opportunities in the United States

Oral-only bundling creates the clearest commercial opening. Generic cinacalcet, available since 2018, gives dialysis chains a lower-cost calcimimetic to place inside the bundle, and suppliers that document calciphylaxis prevention outcomes will win preferred-formulary status. Ardelyx's Xphozah, approved in 2023 as an add-on phosphate control agent, offers a second route for chains managing persistent hyperphosphatemia alongside binders from Sanofi and Akebia's Auryxia.

The ESRD Treatment Choices Model, launched in January 2021 to reward home dialysis and transplant, shifts care toward home settings where calciphylaxis wounds need topical wound-care supply rather than in-centre infusion. Companies offering home-deliverable wound dressings and remote mineral monitoring can capture that volume. Sodium thiosulfate sponsors that secure an FDA indication would gain protected pricing, an advantage compounded supply cannot offer.

Market at a Glance

Leading Market Participants

• Amgen
• DaVita
• Fresenius Medical Care
• Baxter International
• Akebia Therapeutics
• Ardelyx
• CSL Vifor
• Sanofi
• American Renal Associates
• Hope Pharmaceuticals

Regulatory and Policy Environment for Calciphylaxis in the United States

The primary legislation is Section 1881 of the Social Security Act, which establishes Medicare end-stage renal disease coverage. It is implemented through 42 CFR Part 413 for the ESRD Prospective Payment System and 42 CFR Part 494 for facility Conditions for Coverage, both administered by the Centers for Medicare and Medicaid Services. The Food and Drug Administration administers the Federal Food, Drug, and Cosmetic Act and the Drug Quality and Security Act of 2013, requiring 503B registration and USP <797> sterile practice. Upcoming changes include the CY2027 ESRD PPS proposed rule, expected in mid-2026, and the third Medicare drug price negotiation cycle, whose maximum fair prices publish by 30 November 2026 for effect on 1 January 2028.

Compared with regional peers, the framework is distinctive. Canada funds dialysis through provincial budgets, so cost pressure falls on provinces rather than individual providers. Germany's AMNOG process, enacted in 2010, requires the Federal Joint Committee to assess added benefit before pricing, a step the U.S. lacks for most off-label thiosulfate use. Japan's Ministry of Health, Labour and Welfare revises drug prices on a regular cycle, whereas U.S. pricing for calciphylaxis drugs depends on federal rulemaking and the Inflation Reduction Act timetable, making it more fragmented.

Long-Term Policy Outlook for Calciphylaxis in the United States

By 2032 the most consequential policy shift will be Medicare drug price negotiation. Branded small-molecule drugs selected by the Centers for Medicare and Medicaid Services face maximum fair prices from 1 January 2028 under the Inflation Reduction Act, compressing margins for branded cinacalcet and pushing volume toward generics. Dialysis chains will hold stronger negotiating positions, expanding oral-only formulary control and limiting uptake of premium alternatives.

Value-based payment will extend further. Calciphylaxis mortality commonly exceeds 50 percent within one year, making prevention metrics the logical next addition to dialysis quality programmes such as the ESRD Quality Incentive Program. The market will consolidate around suppliers with documented prevention evidence, while compounded thiosulfate remains a bridge until a sponsor secures an FDA indication.